2023年11月11日 · The DAPA-MI trial extends the evidence from prior SGLT2 inhibitor trials and shows clinically relevant, largely cardiometabolic, benefits of dapagliflozin in patients …

2023年11月11日 · The DAPA-MI trial showed that dapagliflozin use among patients with acute MI without a history of DM or chronic HF has better cardiometabolic outcomes compared with …

BACKGROUND: In patients with acute myocardial infarction (MI), therapies that could further reduce the risk of adverse cardiovascular and metabolic outcomes are needed. METHODS: In …

DAPA-MI: Digital technologies underpin world’s first indication-seeking registry-based randomised controlled outcomes trial. Innovative approaches enhance patient experience and drive 50% …

Methods: DAPA-MI is a multicenter, parallel-group, registry-based, randomized, double-blind, placebo-controlled phase 3 trial in patients without known diabetes or established HF, …

2023年11月18日 · The DAPA-MI (dapagliflozin in patients with MI) trial (NCT04564742) tested whether dapagliflozin 10 mg (once daily, in addition to standard of care) was beneficial for …

2025年3月29日 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been shown to be effective in reducing heart-failure–related admissions across a wide spectrum of high-risk …

2023年12月1日 · DAPA-MI is a multicenter, parallel-group, registry-based, randomized, double-blind, placebo-controlled phase 3 trial in patients without known diabetes or established HF, …

This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for …

DAPA-MI is a multicenter, parallel-group, registry-based, randomized, double-blind, placebo-controlled phase 3 trial in patients without known diabetes or established HF, presenting with …